🧬 ART Drug Interaction Screening Simulator

Building a Complete Medication Inventory Before Screening Begins

Drug interaction screening software is only as reliable as the medication list entered into it. People with HIV commonly take a mix of antiretrovirals, comorbidity medications, over-the-counter analgesics, herbal products, and recreational or gender-affirming substances — many of which patients do not think to mention unless specifically asked. A thorough reconciliation at every visit is the single highest-yield step in interaction prevention.

• 6–8: Average meds per PLWH (prescription + OTC + supplements)
• ~40%: Interactions missed by self-report alone (OTC/herbal omission)
• ~50%: ART patients with ≥1 flagged interaction (in polypharmacy cohorts)
• Multiple: Validated screening tools (Liverpool HIV iChart, Lexicomp, UpToDate)

What a complete medication list must capture

A screening-ready medication list is more than the ART regimen — it must include every substance a patient regularly or intermittently ingests:

• Prescription medications: ART agents, chronic disease therapy (statins, antihypertensives, antidiabetics, anticoagulants, psychiatric medications) • Over-the-counter (OTC) products: antacids, proton pump inhibitors, analgesics (NSAIDs), cold/allergy combinations, laxatives • Vitamins and mineral supplements: calcium, iron, magnesium, multivitamins — frequent sources of INSTI chelation • Herbal and complementary products: St. John's Wort (potent CYP3A4 inducer, contraindicated with most ART), garlic supplements, echinacea • Hormonal therapy: oral contraceptives, gender-affirming hormone therapy — bidirectional interactions with boosted regimens • Recreational and illicit substances: recreational drug use can interact with boosted regimens (e.g., MDMA, ketamine toxicity potentiated by ritonavir)

Each item should be recorded with formulation, dose, frequency, and — critically — how consistently it is actually taken, since interactions with intermittent use (e.g., occasional antacid) require different counseling than daily co-administration.

Common blind spots in patient-reported history

Interaction screening fails most often not because the software is wrong, but because the input list is incomplete. Structured, explicit questioning outperforms open-ended questions:

• Patients rarely volunteer OTC antacids, calcium chews, or multivitamins unless asked directly — these feel like "not real medications" • Herbal and traditional remedies are frequently withheld unless the clinician normalizes asking about them • Recreational substance use is underreported due to stigma; a nonjudgmental, harm-reduction framing improves disclosure • Medications from other prescribers (dermatology, psychiatry, urgent care) are often missing from the primary chart • Every visit — not just ART initiation — should trigger a reconciliation, since interacting medications are frequently added after the regimen is already stable

A single missed entry — an iron supplement taken for anemia, a friend's leftover antacid, a herbal weight-loss product containing St. John's Wort — can silently undermine an otherwise perfectly designed antiretroviral regimen. Reconciliation is not a one-time intake task; it is a repeated screening habit.

Ritonavir and Cobicistat — Potent CYP3A4 Inhibitors With Broad Interaction Potential

Ritonavir and cobicistat are pharmacokinetic "boosters" — neither contributes meaningful antiviral activity at boosting doses, but both are among the most potent CYP3A4 inhibitors used in clinical medicine. By near-completely blocking first-pass and systemic CYP3A4 metabolism, they raise levels of co-administered protease inhibitors or elvitegravir into the therapeutic range — but the same mechanism indiscriminately elevates any other CYP3A4 substrate taken concurrently, sometimes to toxic concentrations.

• >90%: Ritonavir CYP3A4 inhibition (near-complete first-pass blockade)
• None: Cobicistat antiviral activity (pure pharmacokinetic enhancer)
• Contraindicated: Simvastatin/lovastatin + boosted PI (rhabdomyolysis risk)
• Cushing syndrome risk: Inhaled fluticasone + ritonavir (iatrogenic adrenal suppression)

Mechanism of CYP3A4-mediated boosting

CYP3A4 is the most abundant cytochrome P450 enzyme in the human liver and gut wall, responsible for metabolizing roughly half of all marketed small-molecule drugs.

• Ritonavir binds CYP3A4 with high affinity, mechanism-based (irreversible) inhibition that persists after the drug itself is cleared • Cobicistat is a structural analog of elvitegravir-boosting design, engineered to inhibit CYP3A4 without antiretroviral activity or resistance liability • Both agents also inhibit P-glycoprotein (P-gp) and other transporters, compounding interactions beyond CYP3A4 substrates alone • The result: co-administered protease inhibitors (atazanavir, darunavir) or elvitegravir achieve trough concentrations that would otherwise require impractical dosing frequency

This same mechanism is entirely non-selective — any other CYP3A4 substrate absorbed through the gut wall or metabolized hepatically is affected identically.

High-risk drug classes with boosted regimens

Three drug classes account for the majority of clinically significant boosted-regimen interactions flagged in screening:

• Statins: simvastatin and lovastatin are contraindicated with ritonavir/cobicistat (risk of rhabdomyolysis from massively elevated exposure); atorvastatin requires dose capping; pravastatin and pitavastatin are CYP3A4-independent and preferred alternatives • Corticosteroids: inhaled/intranasal fluticasone and budesonide undergo extensive first-pass CYP3A4 metabolism — boosting can raise systemic exposure enough to cause iatrogenic Cushing syndrome and adrenal suppression even though the steroid is only "locally" administered • Anticoagulants: rivaroxaban and certain DOACs are CYP3A4/P-gp substrates whose levels rise unpredictably with boosting, increasing bleeding risk; warfarin interactions are variable and require closer INR monitoring rather than automatic contraindication

Other notable interactions include certain calcium channel blockers, PDE5 inhibitors (sildenafil dose reduction required), and some benzodiazepines (midazolam, triazolam contraindicated).

Case reports of iatrogenic Cushing syndrome and adrenal crisis from inhaled or intranasal fluticasone combined with ritonavir-boosted regimens illustrate how easily a seemingly "topical" or "local" medication can become systemically dangerous once CYP3A4 clearance is removed from the equation.

Divalent and Trivalent Cation Chelation of Integrase Inhibitors

Integrase strand transfer inhibitors (dolutegravir, bictegravir, elvitegravir, raltegravir) share a chemical structure that readily chelates polyvalent metal cations. When co-administered with antacids, multivitamins, or mineral supplements containing calcium, iron, magnesium, or aluminum, the INSTI binds the cation to form a poorly soluble complex — reducing oral bioavailability by as much as 90% and risking virologic failure and resistance.

• up to 90%: INSTI absorption reduction (unspaced calcium/iron co-administration)
• 2 h before / 6 h after: Recommended separation window (cation-containing products)
• DTG · BIC · EVG · RAL: INSTIs affected (all chelation-prone)
• DTG/BIC with a meal: Same-time exception (food can offset some chelation)

Chelation chemistry — why polyvalent cations disable INSTIs

INSTIs contain a metal-binding pharmacophore — a triad of coplanar oxygen atoms designed to coordinate the Mg²⁺ ions at the HIV integrase active site. This is precisely what gives the drug class its antiviral mechanism: chelating the enzyme's catalytic magnesium blocks strand transfer.

The same chemistry that makes INSTIs effective against the viral enzyme also makes them promiscuous chelators of any polyvalent cation encountered in the gastrointestinal lumen:

• Calcium (antacids, calcium carbonate supplements, fortified foods) • Iron (ferrous sulfate, prenatal vitamins) • Magnesium (antacids, laxatives, magnesium supplements) • Aluminum (aluminum hydroxide antacids) • Zinc (some multivitamin formulations)

When the INSTI binds one of these cations in the gut instead of remaining free for absorption, it forms a large, poorly soluble complex that is not efficiently absorbed across the intestinal epithelium — the drug is excreted largely unchanged, with plasma concentrations dropping toward subtherapeutic levels.

Clinical spacing recommendations and formulation nuances

Because chelation is a physical/chemical event in the gut lumen rather than a metabolic interaction, it is managed by separating administration in time rather than avoiding the combination altogether:

• General rule: take the INSTI 2 hours before, or 6 hours after, any calcium- or iron-containing product • Dolutegravir and bictegravir have a partial exception: when taken together with a meal (rather than fasting), the food effect can partially offset chelation from a single co-administered supplement, though separation is still preferred whenever practical • Raltegravir and elvitegravir/cobicistat have less flexibility and should follow strict separation • Iron and calcium supplements taken for anemia or bone health in pregnant or postmenopausal patients on ART are a particularly high-risk, easily missed scenario • Patient counseling should explicitly name the specific products likely to be encountered — daily multivitamins, calcium-fortified orange juice, prenatal vitamins, and common antacid brands — rather than relying on a generic "avoid antacids" instruction

Unspaced co-administration of an INSTI with a calcium or iron supplement can silently drop antiretroviral exposure into a subtherapeutic range without producing any acute symptoms — the first sign may be a rebound in viral load at a routine follow-up, potentially compounded by the emergence of integrase resistance mutations.

Classifying Detected Interactions by Clinical Severity

Not every flagged interaction demands the same response. A robust screening workflow triages each detected interaction into one of three severity tiers — contraindicated, dose-adjustment/spacing required, or monitoring-level — so that clinical effort is focused where the risk is greatest, rather than treating every flagged pair identically.

• Regimen change required: Contraindicated tier (e.g., simvastatin + boosted PI)
• Modify dose or timing: Dose-adjust / spacing tier (e.g., INSTI + calcium supplement)
• Routine labs / follow-up: Monitor-only tier (e.g., QT-prolonging combinations)
• Red / amber / green: Triage convention (traffic-light severity rating)

A three-tier classification framework

Most interaction-checking references (Liverpool HIV iChart, Lexicomp) converge on a similar three-tier structure:

• Red — contraindicated: the interaction produces a serious, potentially life-threatening effect with no safe way to co-administer (e.g., simvastatin with a boosted protease inhibitor, St. John's Wort with any ART). The resolution is always to avoid the combination — substitute one of the two agents. • Amber — dose adjustment or spacing required: the interaction is manageable with a specific, well-defined mitigation — reduced dose, altered timing, or administration spacing (e.g., INSTI-cation chelation, some anticoagulant dose caps). • Green — potential interaction, monitor: a theoretical or mild interaction where co-administration is acceptable with awareness — additional lab monitoring, symptom vigilance, or periodic dose reassessment (e.g., mild QT-interval additive effects, minor bioavailability shifts).

This tiering converts an undifferentiated list of "interactions found" into an actionable priority list.

The decision pathway from flag to action

Once an interaction is classified, the severity tier maps directly onto a decision pathway:

1. Confirm the interaction is real for this specific patient (correct doses, formulations, and timing as actually taken — not just theoretically possible) 2. For red-tier interactions: identify and implement an alternative agent before the next dose is due; do not attempt dose reduction as a workaround for a contraindicated pairing 3. For amber-tier interactions: implement the specific, validated mitigation (spacing window, dose cap) and document it clearly for the patient and future prescribers 4. For green-tier interactions: document the awareness, schedule any recommended monitoring (e.g., ECG, lipid panel, renal function), and reassess at the next visit 5. Re-screen the full medication list whenever any single medication changes — a new addition can change the severity tier of an existing, previously "safe" combination

Severity classification is not static — a green-tier interaction can become amber or red if a dose increases, a new interacting medication is added, or renal/hepatic function changes. Re-screening at every medication change, not just at ART initiation, is essential.

Resolving Flagged Interactions — Substitution, Spacing, or Monitoring

Once an interaction has been detected and classified, resolution follows one of three pathways matched to its severity: substituting an alternative agent, separating dose timing, or intensifying monitoring. The goal is always to preserve virologic suppression and treatment adherence while eliminating or managing the clinically significant interaction.

• Most durable fix: Alternative agent substitution (e.g., switch to an INSTI-based regimen)
• Effective for chelation: Dose-timing separation (2 h before / 6 h after rule)
• Labs + closer follow-up: Enhanced monitoring (when substitution is not feasible)
• Unboosted INSTI-based first-line: Regimen simplification trend (fewer interactions than boosted PI regimens)

Choosing the right resolution pathway

Resolution strategy depends on the interaction mechanism and severity tier established in the previous stage:

• Alternative agent substitution: the most durable solution for contraindicated (red-tier) interactions. Examples include switching simvastatin to pravastatin or pitavastatin, or moving a patient from a boosted protease-inhibitor regimen to an unboosted INSTI-based regimen (dolutegravir or bictegravir) when the interacting comedication cannot itself be changed. • Dose-timing separation: the standard fix for chelation interactions — separating an INSTI from calcium, iron, or magnesium-containing products by the recommended window preserves both medications without changing either regimen. • Enhanced monitoring: reserved for interactions that cannot be fully eliminated by substitution or spacing, or where the interacting comedication is essential and irreplaceable — e.g., closer INR checks with warfarin, periodic ECG for additive QT effects, or more frequent viral load checks after any regimen change.

The overall trend in modern ART is toward unboosted, INSTI-based first-line regimens specifically because they carry substantially fewer CYP3A4-mediated interactions than boosted protease-inhibitor regimens — shifting the dominant residual interaction concern toward cation chelation, which is manageable through counseling alone.

Documentation, counseling, and re-screening

A resolved interaction is only truly resolved when it is documented and communicated:

• Update the medication list and the interaction-screening record so future automated checks and future prescribers see the resolution, not just the original flag • Counsel the patient explicitly and in plain language: which products to separate, by how many hours, and why — generic "watch for interactions" counseling has poor adherence to spacing instructions • Provide simple anchors (e.g., "take your HIV medicine with breakfast, take your calcium supplement at dinner") rather than abstract hour counts alone • Re-screen the full list at every subsequent visit or medication change — resolution of one interaction does not exempt the regimen from future screening • Pharmacist-led medication therapy management and interaction screening at ART initiation and at each refill has been shown to meaningfully reduce clinically significant, unresolved drug interactions in people with HIV

Pharmacist-integrated interaction screening — repeated at every refill, not only at ART initiation — is one of the highest-yield, lowest-cost interventions for reducing clinically significant, unresolved antiretroviral drug interactions in real-world care.